Adverse events of ONO-4641 appeared to be dose related and included cardiovascular events, such as a slower heartbeat, blood pressure changes, and an AV block, which is the impairment of the conduction between the atria and ventricles of the heart. Other adverse events included liver enzyme elevations. In addition, grade four lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in four percent of people receiving the 0.15 mg dose of ONO-4641 and in one percent of those receiving the 0.10 mg dose.
"In light of recent issues in the oral MS drug market, this is welcome news," said study author Timothy Vollmer, MD, of the University of Colorado in Denver and a Fellow with the American Academy of Neurology.
cheerleader wrote:I suggest they call this new drug, "Oh, NO!!"
Users browsing this forum: Jaded